Human TRIM5α expression levels and reduced susceptibility to HIV-I infection

Journal of Infectious Diseases

Volumn 199, Issue 11, 2009, Pages 1657-1663

  Sewram, Shamman ^a,b   Singh, Ravesh ^a   Kormuth, Emil ^b   Werner, Lise ^b   Mlisana, Koleka ^b   Karim, S S Abdool ^b   Ndung'u, Thumbi ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; MESSENGER RNA; TRIPARTITE MOTIF PROTEIN 5; CARRIER PROTEIN; TRIM5 PROTEIN, HUMAN;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SEROCONVERSION; VIREMIA; VIRUS LOAD; VIRUS TYPING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; KINETICS; POLYMERASE CHAIN REACTION; SOUTH AFRICA; TIME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CARRIER PROTEINS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HIV SEROPOSITIVITY; HIV-1; HUMANS; KINETICS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOUTH AFRICA; TIME FACTORS; VIREMIA;

EID: 67650675663     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/598861     Document Type: Article

References (24)

1. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5a restricts HIV-1 infection in Old World monkeys. Nature 2004; 427:848-53.
2. Stremlau M, Perron M, Lee M, et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5a restriction factor. Proc Natl Acad Sci USA 2006; 103:5514-9.
3. Perron MJ, Stremlau M, Lee M, Javanbakht H, Song B, Sodroski J. The human TRIM5a restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J Virol 2007; 81:2138-48.
4. Sakuma R, Noser JA, Ohmine S, Ikeda Y. Rhesus monkey TRIM5a restricts HIV-I production through rapid degradation of viral Gag polyproteins. Nat Med 2007; 13:631-5.
5. Zhang F, Perez-Caballero D, Hatziioannou T, Bieniasz PD. No effect of endogenous TRIM5a on HIV-I production. Nat Med 2008; 14:235-6 (author reply, 236-8).
6. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog2008;4:el6.
7. Kaumanns P, Hagmann I, Dittmar MT. Human TRIM5a mediated restriction of different HIV-I subtypes and Lv2 sensitive and insensitive HIV-2 variants. Retrovirology 2006; 3:79.
8. Javanbakht H, An P, Gold B, et al. Effects of human TRIM5a polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 2006; 354:15-27.
9. Speelmon EC, Livingston-Rosanoff D, Li SS, et al. Genetic association of the antiviral restriction factor TRIM5a with human immunodeficiency virus type 1 infection. J Virol 2006; 80:2463-71.
10. van Manen D, Rits MA, Beugeling C, van Dort K, Schuitemaker H, Kootstra NA. The effect of Trim5 polymorphisms on the clinical course of HIV-I infection. PLoS Pathog 2008; 4:el8.
11. Kootstra NA, Navis M, Beugeling C, van Dort KA, Schuitemaker H. The presence of the Trim5a escape mutation H87Q in the capsid of late stage HIV-I variants is preceded by a prolonged asymptomatic infection phase. AIDS 2007; 21:2015-23.
12. van Loggerenberg F, Mlisana K, Williamson C, et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and expe-riences of the CAPRISA 002 acute infection study. PLoS ONE 2008; 3: el954.
13. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-16.
14. Hilleman MR. Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc Natl Acad Sci USA 2004; 101:14560-6.
15. Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008; 8:259-68.
16. Gasper-Smith N, Crossman DM, Whitesides JF, et al. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-I) transmission: implications for HIV-I vaccine design. J Virol 2008; 82:7700-10.
17. Baumann JG. Intracellular restriction factors in mammalian cells-an ancient defense system finds a modern foe. Curr HIV Res 2006; 4:14168.
18. Goff SP. Genetic control of retrovirus susceptibility in mammalian cells. Annu Rev Genet 2004; 38:61-85.
19. Sakuma R, Mael AA, Ikeda Y. Alpha interferon enhances TRIM5amediated antiviral activities in human and rhesus monkey cells. J Virol 2007;81:10201-6.
20. Kamga I, Kahi S, Develioglu L, et al. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis 2005; 192:303-10.
21. Asaoka K, Ikeda K, Hishinuma T, Horie-Inoue K, Takeda S, Inoue S. A retrovirus restriction factor TRIM5a is transcriptionally regulated by interferons. Biochem Biophys Res Commun 2005; 338:1950-6.
22. Jin X, Brooks A, Chen H, Bennett R, Reichman R, Smith H. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 2005; 79:11513- 6.
23. Cho SJ, Drechsler H, Burke RC, Arens MQ, Powderly W, Davidson NO. APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. J Virol 2006; 80:2069-72.
24. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 2008; 82:3125-30.1